Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2010-07-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study
NCT01859481
A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine
NCT00174395
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
NCT01978496
The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects
NCT04401137
Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs
NCT00634985
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment A
1 X 20 mg eletriptan
Eletriptan commercial tablet
20 mg tablet, single dose
Treatment B
1 X 40 mg eletriptan
Eletriptan commercial tablet
40 mg tablet, single dose of 1 X 40 mg
Treatment C
2 X 40 mg eletriptan
Eletriptan commercial tablet
40 mg tablet, single dose of 2 X 40 mg
Treatment D
1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose
Eletriptan commercial tablet
40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eletriptan commercial tablet
20 mg tablet, single dose
Eletriptan commercial tablet
40 mg tablet, single dose of 1 X 40 mg
Eletriptan commercial tablet
40 mg tablet, single dose of 2 X 40 mg
Eletriptan commercial tablet
40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2
* provide informed consent
Exclusion Criteria
* any condition possibly affecting drug absorption
* positive urine drug screen
18 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1601126
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.